By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Small Interference RNAs (siRNAs). According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Structural modifications of the siRNA backbone improved its physiochemical properties for incorporating in gene carriers without loss of gene-silencing efficacy. These modifications provide a wider variety of choice of vector systems for siRNA delivery."
The news reporters obtained a quote from the research from Biomedical Research Institute, "We developed a tumor-targeted siRNA delivery system using polymerized siRNA (poly-siRNA) and natural polymer gelatin. The polymerized siRNA (poly-siRNA) was prepared through self-polymerization of thiol groups at the 5'-end of sense and anti-sense strands of siRNA and was encapsulated in the self-assembled thiolated gelatin (tGel) nanoparticles (NPs) with chemical cross-linking. The resulting poly-siRNA-tGel (psi-tGel) nanoparticles (average of 145 nm in diameter) protect siRNA molecules from enzymatic degradation, and can be reversibly reduced to release functional siRNA molecules in reductive conditions. The psi-tGel NPs presented efficient siRNA delivery in red fluorescence protein expressing melanoma cells (RFP/B16F10) to down-regulate target gene expression. In addition, the NPs showed low toxicity at a high transfection dose of 125 ?g/ml psi-tGel NPs, which included 1 ?M of siRNA molecules. In tumor-bearing mice, the psi-tGel NPs showed 2.8 times higher tumor accumulation than the naked poly-siRNA, suggesting tumor-targeted siRNA delivery of psi-tGel NPs. Importantly, the psi-tGel NPs induced effective tumor RFP gene silencing in vivo without remarkable toxicity."
According to the news reporters, the research concluded: "The psi-tGel NPs have great potential for a systemic siRNA delivery system for cancer therapy, based on their characteristics of low toxicity, tumor accumulation, and effective siRNA delivery."
For more information on this research see: Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. Journal of Controlled Release, 2013;172(1):358-66. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news correspondents report that additional information may be obtained by contacting S.J. Lee, Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Hwarangno 14-gil 6, Seongbuk-gu, Seoul 136-791, South Korea. Additional authors for this research include J.Y. Yhee, S.H. Kim, I.C. Kwon and K. Kim (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Asia, Seoul, Genetics, South Korea, Nanoparticle, Nanotechnology, Emerging Technologies, Small Interference RNAs (siRNAs).
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC